Market closed·Syncing…
Market closed · Close · 18 Nov

Suven Life Sciences Limited SUVENshare price and chart

Suven Life Sciences closed at ₹265.65 on 18 November 2026, down 1.12% on the day. The 52-week range is ₹124.11 to ₹403.35.

₹265.65The price one share last traded at, in rupees.▼ 1.12% · ₹3.01
52-wk low ₹12451% up the rangeThe highest and lowest price the share has traded at in the past year, and where today's price sits between the two.high ₹403

Daily candlesEach candle is one trading day. The chart opens on the last year; drag back past the start or open full screen and the rest loads, back to listing (or the first day in our data). The body runs from the open to the close, the thin lines to the high and low. Green closed up, red closed down.

Loading prices…

Split and bonus adjusted daily candles. Drag back past the start, or open full screen, and its whole history loads. Scroll or pinch to zoom; full screen adds indicators, drawing and measuring.

Test a strategy on SUVEN

Real prices, every charge counted. Pick one or write your own.
What Suven Life Sciences Limited does
A short, human-reviewed summary of the business, written from public sources. Background, not analysis, and not updated intraday.
business summary

Suven Life Sciences provides scientific research and technical services, 100% of its turnover, to pharmaceutical and life sciences companies. Exports are 70% of turnover.

1
1Sector

Healthcare Services

2
2What it sells

Pharmaceutical research services

3
3Who buys it

Pharma and life sciences companies

Technical snapshotHow the share has been behaving: its momentum, its trend, how much of the trading was real buying to keep, and its returns.

EOD 18 Nov
RSI (14) · 30 oversold, 70 overboughtA score from 0 to 100 showing how strong recent up days were against recent down days.
40.8Neutral
0 oversold3070overbought 100
Delivery · bought to hold vs churnOf all the shares traded in a day, the share that actually changed hands and went into someone's demat account, rather than being bought and sold the same day.
44.2%Near average
today 44.2%20d avg 41.4%

The share of traded quantity that was actually delivered (not squared off intraday) - high delivery vs its 20-session average suggests real buying or holding, not just churn.

vs 50 DMAHow far today's close is above or below the average closing price of the last 50 trading days. It shows the medium-term trend.▼ 11.8%vs 200 DMAHow far today's close is above or below the average closing price of the last 200 trading days, about ten months. It is the most watched line for the long-term trend.+3.7%1 monthHow much the share price has changed over the period.▼ 8.4%3 monthsHow much the share price has changed over the period.▼ 21.8%1 yearHow much the share price has changed over the period.+41.3%Vol 30dHow much the share has actually been moving day to day, stated as a yearly percentage. 30% means it swung roughly 30% a year at that pace.46.6%

Returns and valuationWhat the market pays for this company and how well the business uses its money.

Books to 30 Sept 2026
Market capWhat the whole company is worth on the stock market: share price times the number of shares. It measures size, not quality.₹7,506 Cr18 NovReturn on equityHow much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money.-78.8%full year FY26Price to bookThe share price against the shareholders' money per share on the balance sheet. It asks what you pay for each rupee the owners have in the business.16.55xbooks of Sept 2026Return on capitalHow much operating profit the company made on all the money in the business, whether it came from owners or lenders.-78.8%full year FY26Dividend yieldThe cash paid out in a year as a percentage of today's share price. A 2% yield means ₹2 a year on a ₹100 share.0.00%last 12 monthsDebt to equityBorrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings.0.00xbooks of Sept 2026

Against its sectorWhere this company ranks among similar companies on each measure.

Healthcare Services · 49 peers · medians
Revenue growthHow much sales grew in the latest quarter against the same quarter a year earlier.30.4%vs 22.75% median
Lowest: ONEGLOBAL -50.77%Highest: GKSL 194.62%

What the numbers sayShort plain statements about this company's latest figures.

Written by fixed rules

Latest quarterIn the quarter to September 2026, sales rose 30.4% from a year earlier to ₹1.2 cr and the loss was ₹107 cr against ₹77.3 cr a year earlier.

Going well
  • No borrowings at the FY26 balance sheet.
  • No promoter shares were pledged at the end of September 2026.
Worth watching
  • Reported a loss in FY24 and FY25 and FY26.
  • Operating margin fell from -933.3% in FY23 to -4007.0% in FY26.
  • Profit before interest covered interest -1380.5 times in FY26 (₹0 cr of interest).
  • Return on equity stayed under 10% from FY24 to FY26 (highest -32.6%).
  • Promoter holding fell 4.8 points over 5 quarters (70.27% to 65.47%).

Each line is written by a fixed rule from the company's own filings and share price, and names the figures it uses. It describes what happened; it is not advice about the share.

Share price reaction to resultsWhat the share price did around each recent quarterly result.

Over the last 19 results, the share rose on 10 and fell on 9, and moved by 3% or more on 9.

+20%
-20%
Q1 FY23Q1 FY24Q1 FY25Q1 FY26Q1 FY27

Q1 FY27: results filed 6 Aug 2026. The share went from its close on 5 Aug 2026 to its close on 7 Aug 2026 -2.50%.

Dividend historyCash the company has paid per share, year by year.

₹565 in 2019
Paid 4 of 4 yrs
what 2019's payouts come to on ₹1 lakh at today's price · nothing declared in the last twelve months
What each year paid, on ₹1 lakh
753
376
565
565
16
17
18
19

2019 paid ₹1.50 per share, about ₹565 on ₹1 lakh at today's price. Dividends are at the company's discretion and can be cut or skipped.

What it has returnedThe yearly growth rate in the share price over each period, as if it had grown smoothly.

Price only, before dividends
+42.8%a year, over 10 years
1 yr
+53.8%
3 yr
+48.3%
5 yr
+25.3%
10 yr
+42.8%

Held for 10 years this compounded at +42.8% a year. The last twelve months were up +53.8%. Price only, before dividends.

Shareholding patternThe share of the company held by its promoters, by foreign and domestic institutions, and by the public, quarter by quarter.

Who owns it
65.47%promoter holding, as of 2026-09-30+5.5 pts since 2021
Promoter share since listing
2021-0965.47% now, drawn to its own range2026-09
Who owns it todayas of Sep 26
65.5%
31.9%
Promoter65.5%Foreign (FII)0.5%Domestic (DII)2.2%Public & others31.9%
Who is buying, who is leavingJul 25 to Sep 26
Promoter65.5%-2.0 pts
Foreign (FII)0.5%-0.1 pts
Domestic (DII)2.2%-1.2 pts

Each line is that holder's share of all shares over the last 8 quarters, drawn to its own scale - the printed change is the size of the move. Mutual funds and insurers sit inside the domestic figure; hover the bar above for that split.

The promoter/promoter-group stake as a percentage of total shares, each quarter since listing. A rising line means promoters are adding to their stake; a falling one often means dilution, pledge-driven sales, or stake sales to new investors.

Promoter pledgeThe share of promoters' holdings given to lenders as security for a loan.0.00%of promoter shares, as at 2026-09-30

Insider tradesPurchases and sales of the company's own shares by promoters, directors and senior staff.

Last 18 months
Buy
Jasti Property and Equity Holdings Private Limited
Promoter Group · 10-Mar-2026 10:48
3.2 Cr sh
₹425.7 Cr
Buy
Jasti Property and Equity Holdings Private Limited
Promoter Group · 07-Jul-2025 18:47
3.2 Cr sh
₹425.7 Cr

Recent announcementsThe company's own filings to the exchange in the last six months: results, board meetings, investor calls and more, each with its source document.

Last 6 months
Press Release (Revised)16-Nov-2026

Suven Life Sciences Limited has informed the Exchange regarding a revised press release dated November 16, 2026, titled "Please find enclosed the Revised News Release of our Company".

Press Release16-Nov-2026

Suven Life Sciences Limited has informed the Exchange regarding a press release dated November 16, 2026, titled "Please find enclosed News Release of our Company".

Press Release12-Nov-2026

Suven Life Sciences Limited has informed the Exchange regarding a press release dated November 12, 2026, titled "Suven Life Sciences to Present Seven Scientific Posters Highlighting Its CNS Drug Discovery and Development Pipeline at Neuroscience 2026 (SfN), Washington DC, USA".

Monitoring Agency Report06-Nov-2026

Monitoring Agency Report

Copy of Newspaper Publication06-Nov-2026

Suven Life Sciences Limited has informed the Exchange about Copy of Newspaper Publication

Outcome of Board Meeting05-Nov-2026

Suven Life Sciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.

Copy of Newspaper Publication23-Oct-2026

Suven Life Sciences Limited has informed the Exchange about Copy of Newspaper Publication

Certificate under SEBI (Depositories and Participants) Regulations, 201807-Oct-2026

Suven Life Sciences Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

Press Release03-Sep-2026

Suven Life Sciences Limited has informed the Exchange regarding a press release dated September 03, 2026, titled "Suven Life Sciences Announces Completion of Patient Enrollment in Global Phase-3 Study of Masupirdine (SUVN-502) for Agitation Associated with Alzheimer s Dementia (AAD)".

Shareholders meeting25-Aug-2026

Suven Life Sciences Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 25, 2026. Further, the company has submitted the Exchange a copy of Srutinizers report along with voting results.

Monitoring Agency Report11-Aug-2026

Monitoring Agency Report for the quarter ended June 30, 2026

Copy of Newspaper Publication07-Aug-2026

Suven Life Sciences Limited has informed the Exchange about Copy of Newspaper Publication

Outcome of Board Meeting06-Aug-2026

Suven Life Sciences Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.

Copy of Newspaper Publication31-Jul-2026

Suven Life Sciences Limited has informed the Exchange about Copy of Newspaper Publication

General Updates30-Jul-2026

Suven Life Sciences Limited has informed the Exchange about Letter to Shareholders regarding Annual Report 2025-26

Backtest idea · SUVENMACD momentum

Momentum turning up, only while the long trend is up.

BuyMACD crosses above signal, price above 200-day SMA
SellMACD crosses back below
Real prices · every charge countedRun on SUVEN
Backtest idea · SUVENLower band bounce

Buys a stretch below the usual range, sells on the way back.

BuyCloses below the lower Bollinger band
SellBack at the middle band, or 15 days
Real prices · every charge countedRun on SUVEN
Backtest idea · SUVENSupertrend rider

Stays in while the trend line says up, out when it flips.

BuySupertrend turns up
SellSupertrend turns down
Real prices · every charge countedRun on SUVEN
Your own ideaWrite a rule for SUVEN in plain English“Buy SUVEN when …”
Start writing
Buy the dip on SUVENBuy when RSI(14) drops below 30
52-week high breakout on SUVENBuy when closes at a 52-week high
Golden cross on SUVENBuy when 50-day EMA crosses above 200-day
Stochastic oversold on SUVENBuy when stochastic %K drops below 20
Pullback in an uptrend on SUVENBuy when RSI(14) below 40, price above 200-day EMA

Key ratios at a glanceThe eight figures most people check first, each placed against companies in the same industry.

Against its sector
Market capWhat the whole company is worth on the stock market: share price times the number of shares. It measures size, not quality.
₹7,506 cr
Larger than 59% of 49 peers
sector middle ₹2,819 cr
Price to bookThe share price against the shareholders' money per share on the balance sheet. It asks what you pay for each rupee the owners have in the business.
16.6x
Highest of 45 peers
sector middle 5.4x
ROEHow much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money.
-78.8%
Lowest of 32 peers
sector middle 13.6%
FY23 -31.5%FY26 -78.8%
ROCEHow much operating profit the company made on all the money in the business, whether it came from owners or lenders.
-78.8%
Lowest of 38 peers
sector middle 16.0%
FY23 -31.4%FY26 -78.8%
Debt to equityBorrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings.
0.00
No borrowings
sector middle 0.15
FY23 0.00FY26 0.00
Dividend yieldThe cash paid out in a year as a percentage of today's share price. A 2% yield means ₹2 a year on a ₹100 share.
0.0%
Lower than 49% of 49 peers
sector middle 0.0%
Sales growthHow much sales grew in the latest quarter against the same quarter a year earlier.
+30.4%
Higher than 64% of 36 peers
sector middle +22.8%
FY23 14.4%FY26 6.0%

Peers are the listed companies in the exchange's own industry group: Healthcare Research Analytics & Technology. Balance-sheet figures are from the latest filed balance sheet; trends show each financial year we hold.

Revenue and profit, year by yearSales and net profit by financial year or by quarter.

Sales and net profit
FY22FY23FY24FY25FY26
SalesNet profitfell vs last yearEach on its own scale · hover a bar for its figures
Op. marginOf every ₹100 of sales, the profit from the main business before depreciation, interest and tax.-4007.0%FY26SalesMoney earned from selling the company's goods and services, before any costs. Also called revenue.₹7 CrFY26Net profitWhat is left for shareholders after all costs, interest and tax.₹-276 CrFY26

Where every ₹100 of sales goesHow each ₹100 the company sold was spent, and how much stayed as profit.

FY26

In FY26, of every ₹100 of sales it kept ₹0.0 as profit. Other income added ₹195.8.

Where it wentPer ₹100 of sales
Running costs₹4107.0Depreciation₹78.9Interest₹2.8
Profit per ₹100, year by year
FY22FY26

How fast it has grownCompound growth a year in sales and profit, over 3 and 5 financial years, beside the latest quarter.

Compounded a year
3 years5 yearsLatest qtr
Sales▼ 19.3%-+30.4%
Profit---
3 and 5 years are compounded a year across full financial years. The latest quarter is against the same quarter a year earlier.

Cash flowProfit is an accounting figure. Cash flow shows the money that really moved: in from the business, out on investments, and to or from lenders and shareholders.

Where the cash went

In FY26 cash fell by ₹7 Cr, after ₹5 Cr spent on plant and equipment.

FY26Cash in or out
Running the business-₹302 Cr
Investing-₹462 Cr
Lenders and shareholders+₹757 Cr
Net change in cash-₹7 Cr

Health check, year by yearMargins, returns and debt for each financial year, so you can see the direction.

MeasureFY23FY24FY25FY26
Sales growthSales in this financial year against the previous one.14.4%-13.3%-42.7%6.0%
Operating marginOf every ₹100 of sales, the profit from the main business before depreciation, interest and tax.-933%-1094%-2494%-4007%
Net marginOf every ₹100 of sales in the year, how much was left as profit after everything.-876%-898%-2399%-3892%
ROEHow much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money.-31.5%-32.6%-84.6%-78.8%
ROCEHow much operating profit the company made on all the money in the business, whether it came from owners or lenders.-31.4%-32.8%-84.6%-78.8%
Debt to equityBorrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings.0.00x0.00x0.00x0.00x
Interest coverHow many times the company's profit before interest could pay its interest bill.-393.3x-529.5x·-1380.5x

Each row against this company's own usual level: green better, red worse, grey close to it.

Backtest idea · SUVENStochastic oversold

Buys when the close sits near the bottom of its recent range.

BuyStochastic %K drops below 20
Sell8% profit, or after 15 days
Real prices · every charge countedRun on SUVEN
Backtest idea · SUVENPullback in an uptrend

Buys a pause inside a rising trend.

BuyRSI(14) below 40, price above 200-day EMA
Sell8% profit, or after 30 days
Real prices · every charge countedRun on SUVEN
Backtest idea · SUVENBuy the dip

Buys after a sharp fall, betting on a bounce.

BuyRSI(14) drops below 30
Sell10% profit, or after 20 days
Real prices · every charge countedRun on SUVEN
Backtest idea · SUVEN52-week high breakout

Buys strength, when the price makes a new one-year high.

BuyCloses at a 52-week high
Sell8% stop loss
Real prices · every charge countedRun on SUVEN
Backtest idea · SUVENGolden cross

Follows the long trend: in when the fast average crosses above the slow one.

Buy50-day EMA crosses above 200-day
SellWhen it crosses back below
Real prices · every charge countedRun on SUVEN
MACD momentum on SUVENBuy when MACD crosses above signal, price above 200-day SMA
Lower band bounce on SUVENBuy when closes below the lower Bollinger band
Supertrend rider on SUVENBuy when supertrend turns up
Buy the dip on SUVENBuy when RSI(14) drops below 30
52-week high breakout on SUVENBuy when closes at a 52-week high

Peers side by sideCompanies in the same exchange-defined industry group, largest first. Tap a heading to sort.

Healthcare Services
CompanyWhat the whole company is worth on the stock market: share price times the number of shares. It measures size, not quality.How many rupees investors pay today for one rupee of the company's yearly profit. A P/E of 20 means paying ₹20 for ₹1 of annual profit.The share price against the shareholders' money per share on the balance sheet. It asks what you pay for each rupee the owners have in the business.How much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money.How much operating profit the company made on all the money in the business, whether it came from owners or lenders.Borrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings.Of every ₹100 of sales, how much is left as profit after all costs, interest and tax.How much sales grew in the latest quarter against the same quarter a year earlier.The cash paid out in a year as a percentage of today's share price. A 2% yield means ₹2 a year on a ₹100 share.
APOLLOHOSP
Apollo Hospitals Enterprise Limited
1.27 L cr56.6x12.0x21.5%20.7%0.508.4%+20.8%0.23%
MAXHEALTH
Max Healthcare Institute Limited
99,555 cr72.0x8.8x14.3%14.4%0.3315.1%+20.3%0.20%
MANIPALHOS
Manipal Health Enterprises Limited
90,610 cr-5.4x--0.34--0.00%
ASTERDM
Aster DM Quality Care Limited
63,719 cr101.0x8.2x10.1%14.8%0.438.7%+136.3%0.41%
FORTIS
Fortis Healthcare Limited
59,910 cr57.7x5.7x11.0%13.5%0.2910.7%+17.3%0.13%
NH
Narayana Hrudayalaya Ltd.
38,651 cr44.7x7.7x19.7%16.0%0.998.4%+73.0%0.24%
MEDANTA
Global Health Limited
38,626 cr62.4x8.9x15.0%17.9%0.1612.1%+33.6%0.03%
LALPATHLAB
Dr. Lal Path Labs Ltd.
32,989 cr56.3x12.0x21.5%29.1%0.0019.4%+19.6%0.89%
KIMS
Krishna Institute of Medical Sciences Limited
31,878 cr145.4x8.1x9.7%9.9%0.834.3%+39.9%0.00%
SYNGENE
Syngene International Limited
17,552 cr93.9x3.6x6.6%9.5%0.015.3%-8.6%0.29%
AGARWALEYE
Dr. Agarwal's Health Care Limited
17,421 cr101.8x7.8x8.3%15.2%0.098.7%+31.4%0.00%
VIJAYA
Vijaya Diagnostic Centre Limited
15,796 cr77.5x14.9x19.7%30.3%0.0022.4%+26.7%0.13%
INDGN
Indegene Limited
15,782 cr38.3x4.7x13.9%18.9%0.009.9%+39.5%0.34%
RAINBOW
Rainbow Childrens Medicare Limited
12,777 cr43.7x7.5x17.9%27.8%0.0015.5%+23.2%0.28%
METROPOLIS
Metropolis Healthcare Limited
11,703 cr52.1x7.1x13.4%19.6%0.0112.7%+15.8%0.35%
YATHARTH
Yatharth Hospital & Trauma Care Services Limited
10,513 cr55.2x5.6x9.9%12.4%0.2412.2%+54.4%0.05%
PARKHOSPS
Park Medi World Limited
10,282 cr37.0x4.8x13.0%17.7%0.2014.7%-0.00%
JLHL
Jupiter Life Line Hospitals Limited
9,494 cr50.7x5.8x13.7%16.0%0.3611.4%+16.0%0.07%
HCG
Healthcare Global Enterprises Limited
8,948 cr844.1x6.6x1.9%9.4%0.520.8%+13.1%0.00%
THYROCARE
Thyrocare Technologies Limited
8,016 cr56.0x14.5x28.7%37.8%0.0015.4%+25.1%1.39%
SUVEN
Suven Life Sciences Limited
7,506 cr-16.6x-78.8%-78.8%0.00-+30.4%0.00%
NEPHROPLUS
Nephrocare Health Services Limited
6,567 cr50.3x5.5x6.9%13.4%0.0711.5%-0.00%
ARTEMISMED
Artemis Medicare Services Limited
5,436 cr47.4x5.5x11.6%14.8%0.2410.0%+13.2%0.13%
INDRAMEDCO
Indraprastha Medical Corporation Limited
3,282 cr17.1x4.0x27.5%37.7%0.0012.3%+8.3%1.12%
KMCSHIL
K M C Speciality Hospitals (India) Limited
3,220 cr52.6x----17.5%+24.1%0.00%
DRAGARWQ
Dr Agarwals Eye Hospital Limited
2,819 cr37.0x----15.3%+22.3%0.07%
VIMTALABS
Vimta Labs Limited
2,087 cr25.9x4.3x18.6%24.8%0.0318.7%+9.9%0.43%
SURAKSHA
Suraksha Diagnostic Limited
1,813 cr43.3x6.6x13.8%24.8%0.0211.9%+25.8%0.14%
KRSNAA
Krsnaa Diagnostics Limited
1,659 cr16.9x1.6x10.9%12.7%0.5711.1%+31.5%0.39%
SHALBY
Shalby Limited
1,285 cr33.5x1.3x3.5%6.7%0.533.2%+9.7%0.00%
GKSL
Gujarat Kidney And Super Speciality Limited
1,196 cr55.6x4.5x6.6%8.6%0.0616.2%+194.6%0.00%
3BBLACKBIO
3B Blackbio Dx Limited
1,134 cr19.1x----35.4%+42.4%0.38%
GPTHEALTH
GPT Healthcare Limited
1,104 cr21.2x3.9x16.3%23.1%0.0510.2%+14.1%0.74%
HEALTHX
Health X Platform Limited
874 cr-1.4x-0.2%-0.04-1.4%+60.7%0.00%
CREDENT
Credent Connect N Care Limited
843 cr-5.9x--0.15--0.00%
UNIHEALTH
Unihealth Hospitals Limited
785 cr-7.6x-16.2%0.13--0.00%
ONEGLOBAL
One Global Service Provider Limited
755 cr12.1x----14.1%-50.8%0.26%
GAUDIUMIVF
Gaudium IVF and Women Health Limited
709 cr28.1x4.3x16.1%20.4%0.0320.8%-0.00%
MOMSBELIEF
Rays of Belief Limited
594 cr-3.9x--0.15--0.00%
CHANDAN
Chandan Healthcare Limited
583 cr-3.4x-22.4%0.32--0.00%

Swipe the table sideways for more columns. Tap a heading to sort. A dash means the figure is not filed or cannot be worked out for that company. A bigger cohort is cut to its 40 largest companies.

Monthly price changeThe share's price change in every calendar month, one row per year, so you can check for yourself whether a month has a pattern.

Month by month
YearJanFebMarAprMayJunJulAugSepOctNovDecYear
2026
-20.1
+10.0
-9.8
+60.9
+31.8
+0.5
+9.4
+27.7
-18.3
-19.2
+7.0
·
+66.5%
11m
2025
+0.6
-19.1
+9.1
+12.2
+92.0
+0.5
+10.7
-21.4
-4.5
-3.3
-12.9
-3.4
+30.0%
2024
+34.1
-5.5
-2.3
+10.4
-16.2
+13.6
+36.6
-0.8
-1.4
-10.7
+3.3
-1.4
+58.4%
2023
-9.7
-9.9
-12.9
+17.8
-3.0
+14.2
+0.6
+1.2
+10.2
+14.9
+3.1
-4.0
+18.0%
2022
+0.1
-11.1
+16.9
-5.8
-9.0
-11.6
+2.5
+1.3
-2.5
-7.2
+3.9
+8.5
-16.6%
2021
-21.8
+19.6
-16.6
+45.6
-8.7
-6.4
-6.4
+1.0
+12.3
+3.1
-8.3
+0.9
-1.6%
2020
+52.1
+165.3
-65.5
+114.7
-25.8
+21.4
-8.4
+30.9
+1.6
-8.1
+0.3
+94.9
+489.7%
2019
-14.5
+24.4
+8.3
+1.5
+2.8
-0.4
-16.0
+14.0
+7.2
+1.6
+11.3
-2.5
+35.6%
2018
+5.7
-12.6
-10.9
+7.3
+6.4
+8.8
+10.7
+21.4
-3.5
-10.4
-0.2
-6.1
+11.4%
2017
+1.3
-1.9
-3.8
+9.3
+3.8
-8.5
-2.9
-1.9
+8.2
+21.4
-8.5
+3.5
+17.6%
Monthly movebelow -10%-10 to -5-5 to -2-2 to 00 to +2+2 to +5+5 to +10above +10%month in progress

Month-on-month change in closing price, adjusted for splits and bonuses but not for dividends, so a large dividend shows up here as a fall. Starts from 1995, when the exchange began trading equities, or from the stock's listing if later. This is a record of what happened, not a forecast.

Deals and filingsLarge trades reported to the exchange, plus the company's documents sorted by type.

DatePartySideQuantityPriceValue
2024-01-11GRAVITON RESEARCH CAPITAL LLP · bulkSELL14,28,543₹121.70₹17.39 Cr
2024-01-11GRAVITON RESEARCH CAPITAL LLP · bulkBUY14,28,543₹121.82₹17.40 Cr
2023-09-13GRAVITON RESEARCH CAPITAL LLP · bulkSELL15,34,944₹78.20₹12.00 Cr
2023-09-13GRAVITON RESEARCH CAPITAL LLP · bulkBUY15,34,944₹78.12₹11.99 Cr
2021-04-23GRAVITON RESEARCH CAPITAL LLP · bulkSELL6,40,960₹109.97₹7.05 Cr
2021-04-23GRAVITON RESEARCH CAPITAL LLP · bulkBUY6,40,960₹109.64₹7.03 Cr
2020-12-17ALPHA LEON ENTERPRISES LLP · bulkBUY6,56,474₹104.94₹6.89 Cr
2020-12-17ALPHA LEON ENTERPRISES LLP · bulkSELL6,27,462₹105.08₹6.59 Cr

The last two years of the company's filings to the exchange, grouped by the exchange's own categories. Each opens the original document.

Read enough? Test SUVEN. “Buy SUVEN when RSI(14) drops below 30, sell at 10% profit or after 20 days.” Real prices, every charge counted.

Run it free